{"id":"W2971309637","doi":"10.1016/j.jtho.2019.08.009","title":"Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Genentech; National Institutes of Health; Sierra Oncology; Bayer Fund; Lung Cancer Research Foundation; Spectrum Pharmaceuticals; Exelixis; GlaxoSmithKline; Bayer; AstraZeneca; Rexanna's Foundation; Boehringer Ingelheim","keywords":"Medicine; Gemcitabine; Immune checkpoint; Immunotherapy; Immune system; Pharmacology; Immunogenic cell death; Blockade; Combination therapy; Chemotherapy; Oncology; Cancer research; Immunology; Internal medicine; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001808282,0.0003916962,0.001201745,0.0003364811,0.0002809231,0.0004448869,0.0002921676,0.0003101974,0.001548742],"category_scores_gemma":[0.0001646343,0.0001630519,0.0004762058,0.0003313206,0.0002838636,0.000353885,0.000248761,0.001126003,0.0002853399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003594768,"about_ca_system_score_gemma":0.000855064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00090027,"about_ca_topic_score_gemma":0.004081792,"domain_scores_codex":[0.9998491,0.00002829524,0.00001149526,0.000016168,0.00002657672,0.00006835898],"domain_scores_gemma":[0.9999145,0.00001398875,0.00001295444,0.000008262457,0.000005836696,0.00004436116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.05866637,0.009120971,0.005308159,0.0009434327,0.0004667481,0.0005408619,0.0001591808,0.003445797,0.7404274,0.0004761119,0.004294449,0.1761505],"study_design_scores_gemma":[0.01253237,0.1795876,0.07450475,0.0001557364,0.00185687,0.0021127,0.000512984,0.01274074,0.6963007,0.0007485272,0.01878831,0.0001588249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950772,0.003360497,0.0002127673,0.0001132078,0.0001040465,0.00004937662,0.0001102915,0.00007653379,0.0008962434],"genre_scores_gemma":[0.9979612,0.0009567254,0.0003013061,0.0000479941,0.00003091551,0.00003645266,0.0001681481,0.000006801541,0.0004904398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001548742,"threshold_uncertainty_score":0.005181015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006612623437811281,"score_gpt":0.2982258224659358,"score_spread":0.2916131990281245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}